Viewing profile — phobar

Good points but you should differentiate between generics and novel therapies that make up for the 190B USD in EU sales.

You commonly sell it back to the insurance company.

Interesting, could you describe one inefficiency that was exploited in the past? I could imagine buying/selling due to spreads between exchanges but is there another not as obvious…

I am curious, dohappen to have a source for that statement?

They are funded by several big pharma companies (from which they have learned a lot in terms of QSAR). One main point of the collaboration is the creation of production ready toolk…